16:39:55 Europe / Stockholm
2021-11-19 11:48:00
  • Revenue grew 12 percent and EBIT 81 percent in Q3
  • PharmaCept acquisition aids market launch of DSM products
  • We maintain our valuation interval of SEK 46.60 – 62.80 per share


Magle Chemoswed’s report for the third quarter illustrated the impressive advances made with regards to the company’s degradable starch microsphere (DSM) technology platform. The acquisition of PharmaCept is set to accelerate the future launch of the company’s DSM products. This entails Magle Chemoswed is on course to fulfil its objective of having five DSM products on the market by the end of 2022. Furthermore, revenue and EBIT in Q3 increased by 12 and 81 percent respectively compared to Q3 2020. This report confirms the growth trajectory we have forecast, and we therefore only make minor adjustments to our valuation model. Hence, we maintain our valuation interval of SEK 46.60 – 62.80 per share.

The full report is available here.